LSL Pharma Group Inc.
LSL Pharma Group Inc. develops, manufactures, and commercializes sterile pharmaceutical products, cosmetic products, and natural health products in Canada, the United States, and internationally. The company offers dietary supplements and vitamins in the tablet and capsule form; niche sterile ophthalmic products in the form of ointments and drops; and cosmetic, pharmaceutical, and natural health … Read more
LSL Pharma Group Inc. (LSL) - Net Assets
Latest net assets as of September 2025: CA$25.38 Million CAD
Based on the latest financial reports, LSL Pharma Group Inc. (LSL) has net assets worth CA$25.38 Million CAD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$60.19 Million) and total liabilities (CA$34.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$25.38 Million |
| % of Total Assets | 42.17% |
| Annual Growth Rate | 35.05% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 85.21 |
LSL Pharma Group Inc. - Net Assets Trend (2020–2024)
This chart illustrates how LSL Pharma Group Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LSL Pharma Group Inc. (2020–2024)
The table below shows the annual net assets of LSL Pharma Group Inc. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CA$24.89 Million | +187.60% |
| 2023-12-31 | CA$8.65 Million | +63.58% |
| 2022-12-31 | CA$5.29 Million | -52.39% |
| 2021-12-31 | CA$11.11 Million | +48.52% |
| 2020-12-31 | CA$7.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LSL Pharma Group Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1484196300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$39.81 Million | 159.93% |
| Total Equity | CA$24.89 Million | 100.00% |
LSL Pharma Group Inc. Competitors by Market Cap
The table below lists competitors of LSL Pharma Group Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IRCE S.p.A
STU:IRQ
|
$24.10 Million |
|
Yulho Co. Ltd
KQ:072770
|
$24.10 Million |
|
Ymc Co. Ltd
KQ:155650
|
$24.10 Million |
|
NevGold Corp
OTCQX:NAUFF
|
$24.10 Million |
|
M&F Bancorp Inc
PINK:MFBP
|
$24.09 Million |
|
MAGURO GROUP PUBLIC COMPANY LIMITED
BK:MAGURO
|
$24.09 Million |
|
SJ Group Co. Ltd
KQ:306040
|
$24.08 Million |
|
Marvipol S.A.
WAR:MVP
|
$24.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LSL Pharma Group Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,655,000 to 24,892,000, a change of 16,237,000 (187.6%).
- Net income of 3,317,000 contributed positively to equity growth.
- New share issuances of 8,230,000 increased equity.
- Other factors increased equity by 4,690,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$3.32 Million | +13.33% |
| Share Issuances | CA$8.23 Million | +33.06% |
| Other Changes | CA$4.69 Million | +18.84% |
| Total Change | CA$- | 187.60% |
Book Value vs Market Value Analysis
This analysis compares LSL Pharma Group Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.88x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.45x to 1.88x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | CA$0.09 | CA$0.41 | x |
| 2021-12-31 | CA$0.14 | CA$0.41 | x |
| 2022-12-31 | CA$0.06 | CA$0.41 | x |
| 2023-12-31 | CA$0.10 | CA$0.41 | x |
| 2024-12-31 | CA$0.22 | CA$0.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LSL Pharma Group Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.33%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.69%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 2.15x
- Recent ROE (13.33%) is above the historical average (-50.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 1.18% | 1.82% | 0.20x | 3.18x | CA$-660.22K |
| 2021 | -15.99% | -20.26% | 0.30x | 2.61x | CA$-2.89 Million |
| 2022 | -152.37% | -98.15% | 0.30x | 5.16x | CA$-8.59 Million |
| 2023 | -97.89% | -84.48% | 0.32x | 3.57x | CA$-9.34 Million |
| 2024 | 13.33% | 18.69% | 0.33x | 2.15x | CA$827.80K |
Industry Comparison
This section compares LSL Pharma Group Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $156,264,111
- Average return on equity (ROE) among peers: -337.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LSL Pharma Group Inc. (LSL) | CA$25.38 Million | 1.18% | 1.37x | $24.09 Million |
| Amotiv Limited (AOV) | $1.03 Billion | 2.34% | 0.02x | $227.52 Million |
| Cannabist Company Holdings Inc (CBST) | $-986.97K | 0.00% | 0.00x | $11.81 Million |
| DRI Healthcare Trust (DHT-U) | $372.34 Million | 3.11% | 0.70x | $450.44 Million |
| GenixPharmaceucticals Corporation (GENX) | $4.01 Million | -41.17% | 0.19x | $451.93K |
| Simply Solventless Concentrates Ltd. (HASH) | $1.78 Million | -130.46% | 0.98x | $2.81 Million |
| The Hempshire Group Corp. (HMPG) | $-835.46K | 0.00% | 0.00x | $515.15K |
| Good Shroom Co Inc (MUSH) | $242.01K | -170.37% | 3.22x | $2.78 Million |
| Navasota Resources Inc. (NAV) | $3.47K | -2698.16% | 31.31x | $132.92K |
| Verano Holdings Corp Ordinary Shares - Class A (Sub Voting) (VRNO) | $-216.50K | 0.00% | 0.00x | $303.72 Million |